In early trading on the 30th, ABL Bio is plunging more than 14%. The drop is seen as a reaction to news that a Parkinson's disease drug candidate it licensed to Sanofi has been pushed down the ...

ABL Bio said on the 19th that the U.S. Food and Drug Administration (FDA) approved the phase 1 investigational new drug (IND) application for its bispecific Antibody-Drug Conjugate (ADC) candidate ...

SAN FRANCISCO — ABL Bio is closing in on another partnership with a global pharmaceutical company for its proprietary Grabody-B technology, a blood-brain barrier shuttle platform designed to improve ...

SEOUL, South Korea, Dec. 26, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for ...

The contemplated transaction remains subject to due diligence, definitive agreements, regulatory approvals and Nasdaq listing requirements; no change to ABL S.A.’s control over ABL Diagnostics at this ...

Energy and marine consultancy ABL has secured new five-year contracts with long-term client Woodside Energy that expands its existing workscope outside of Australia. ABL has been awarded a global ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of Seoul-based ABL Bio, after it struck a $2.6 billion licensing and joint research deal with Eli Lilly for its bispecific antibody ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into the clinic. ABL, a Korean biotech that is partnered with companies ...

Progress Software Corporation (NASDAQ:PRGS) is one of the most undervalued technology stocks to buy according to analysts. On September 29, Progress Software announced the early customer review and ...

Progress Software (PRGS) announced early customer review and testing of the Progress OpenEdge MCP Connector for ABL, a purpose-built integration designed to accelerate development and modernization ...